Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he plans to ensure that the Medicines and Healthcare products Regulatory Agency uses (a) placenta-on-a-chip and (b) other modern test methods in drug testing.

In the development of new medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) does not, itself, carry out experimental studies. Its role is to review reports of studies supplied by drug developers characterising safety and potential efficacy of the drug; these can include placenta-on-a chip, or other methods using human cells.

To be able to make such judgements, MHRA staff need to maintain and develop their knowledge about modern testing methods and to this end, MHRA staff have contributed to organising and have attended meetings where these methods are discussed. For instance, Agency staff contributed to a multi-stakeholder meeting in London in November 2024 organised in conjunction with the National Council for the 3Rs and with the Association of the British Pharmaceutical Industry for which a publication is now under preparation. MHRA staff will attend the Microphysiological Systems World Summit in Brussels in June 2025, where drug testing methods will be a major topic of discussion.

The MHRA’s own laboratory activities include the independent testing of certain biological products, for example, vaccines and anti-toxins, to ensure they meet acceptable standards prior to each batch being released for use. In the small number of products where this work currently relies on use of animals, development of acceptable, validated, alternatives is a major priority; the numbers of animals used in our regulatory science has more than halved in the last 10 years.